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Lack of comprehensive understanding
of DM and its complications, together
with its increasing prevalence, repre-
sent a major unmet medical need.
There is quite a lot known about its
mechanisms, but more is needed.
Reactive oxygen species (ROS) may
hold the answer to this need, but
long-standing misconceptions about
oxidative stress and the inefﬁcacy of
antioxidants have prevented clinical
breakthroughs.
A new understanding of ROS as both
essential signaling molecules and
pathomechanism have led to the iden-
tiﬁcation, at different stages of dia-
betes, of different therapeutically
relevant sources and targets of ROS.
Network pharmacology and precision
diagnostics, currently in advanced
stages of clinical development, in con-
junction with essential lifestyle
changes, will revolutionize the therapy
and prevention of diabetes and its end-
organ damage.
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(CIBERNED), Instituto de InvestigaciónReactive oxygen species (ROS) have been mainly viewed as unwanted by-
products of cellular metabolism, oxidative stress, a sign of a cellular redox
imbalance, and potential disease mechanisms, such as in diabetes mellitus
(DM). Antioxidant therapies, however, have failed to provide clinical beneﬁt.
This paradox can be explained by recent discoveries that ROS have mainly
essential signaling and metabolic functions and evolutionally conserved phys-
iological enzymatic sources. Disease can occur when ROS accumulate in
nonphysiological concentrations, locations, or forms. By focusing on dis-
ease-relevant sources and targets of ROS, and leaving ROS physiology intact,
precise therapeutic interventions are now possible and are entering clinical
trials. Their outcomes are likely to profoundly change our concepts of ROS in
DM and in medicine in general.
A New Approach to Diabetes Mellitus and Reactive Oxygen Species
Diabetes mellitus (DM) and its related end-organ damage, such as diabetic nephropathy,
neuropathy, retinopathy, and cardiomyopathy, are major causes of death and long-term
disability. Their underlying mechanisms are incompletely understood, which is why none of
the current antidiabetic therapies target the underlying causes or are curative, but focus instead
on normalizing surrogate parameters or risk factors such as blood glucose or hypertension [1].
Hence, our lack of mechanistic understanding of lifestyle change-resistant diabetic end-organ
damage, together with the increasing prevalence of DM, represent a signiﬁcant major unmet
medical need.
One mechanism that has been suggested for decades to cause pancreatic b cell dysfunction
and diabetic end-organ damage is ‘oxidative stress’ (see Glossary), originally deﬁned as an
overproduction of reactive oxygen species (ROS). Antioxidants were considered the obvi-
ous therapeutic countermeasure but, clinically, have consistently disappointed [2]. Even worse,
meta-analyses of clinical trials show that antioxidants may not only be ineffective, but harmful,
and even increase mortality [2].
Recently, however, important conceptual breakthroughs in our understanding of ROS in
general and DM in particular explain the failure of antioxidants and point towards entirely
different mechanism-based and possibly curative therapeutic approaches. Our new under-
standing of ROS requires that many long-held misconceptions, such as the ‘redox balance
hypothesis’ and the view that ROS are primarily stressors, disease triggers, and metabolic
waste products, must be overcome. Instead, the many physiological roles of ROS and the
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(Harald H.H.W. Schmidt).DUOX1–2), in addition to their alternatively spliced variants, should be recognized. In particular,
the discovery of NADPH oxidase isoforms, whose only known function is to produce ROS [i.e.,
NOX1, NOX2 (aka gp91phox) NOX3, NOX4, and NOX5], made it clear that ROS are not merely
waste or toxic by-products that need to be removed in order to prevent cellular damage (Box 1).
In contrast, ROS are part of signaling networks that include ROS targets, such as nitric oxide
synthase (NOS) and soluble guanylate cyclase (sGC), and ROS-metabolizing enzymes, in
particular those genetically regulated by nuclear factor (erythroid-derived 2)-like 2 (NRF2)
[3,4]. The differential expression of these players in different subcellular compartments [5]
suggests that a homogenous cell-wide redox level or balance does not exist, but in fact points
to there being differential asynchronous hot spots of ROS signaling within the cell. This then
makes ROS quite similar to other classical signaling mechanisms [6], including those inducing
post-translational protein modiﬁcations such as phosphorylation.
ROS signaling contributes to physiological functions and processes such as the oxidative burst
of the innate immune response, cell proliferation and angiogenesis, vasodilation, hearing,
hormone synthesis, insulin secretion, and insulin sensitivity [3,7,8]. Dysfunction in ROS signal-
ing includes formation of excessive amounts of ROS, appearance of ROS at nonphysiological
subcellular sites or in cell types that normally do not form relevant amounts of ROS, or shifting
from a physiological to a nonphysiological type of ROS [e.g., from hydrogen peroxide (H2O2) to
superoxide].
These mechanistic insights are now leading to new therapeutic concepts for which DM is one
of best understood and most suitable pathologies. Moving forward, ROS-related drug
development will have to focus on the delicate task of identifying the main disease-relevant
sources of deleterious ROS while at the same time leaving essential physiological sources of
ROS and their signaling pathways intact. One example is the selective inhibition of speciﬁc
NOX isoforms or the use of NRF2 agonists that enhance the expression of endogenous
antioxidant enzymes at their physiological sites, which is qualitatively different to exogenous
scavenging antioxidants acting broadly, in all cells and all cellular compartments, and thus in a
nonphysiological manner. As a complicating factor, during the course of disease, the
enzymatic sources of ROS may change. One example of this is the triggering of vascular
dysfunction by NOX1, leading to uncoupling of NOS3, which may become a secondary, yet
quantitatively more relevant source of ROS [9]; another example is ROS-induced ROS release
in mitochondria [10].Box 1. NADPH Oxidase Family
Unlike several ROS sources (e.g., mitochondria, xanthine oxidase, cytochrome P450 enzymes, and uncoupled NOS),
NADPH oxidases are the only enzyme family known to produce ROS as their primary and sole function [5]. NADPH
oxidases are enzyme complexes with a membrane spanning catalytic NOX subunit in addition to other membrane and
cytosolic proteins. There are seven identiﬁed members of the NADPH oxidase family, NOX1–5, and two dual oxidases
(DUOX), DUOX1 and DUOX2. In humans, all seven enzymes are expressed and each NOX isoform has speciﬁc tissue
expression, regulation, and type of ROS produced [3,5].
The main NOX isoforms to be considered in pathophysiology of DM are NOX1 and NOX5, which produce superoxide,
and NOX4, which produces H2O2. NOX3 and the DUOXs have very limited roles in the inner ear and in the synthesis of
thyroid hormone, respectively [87]. NOX2 is a key enzyme of the innate and inﬂammatory response and its inhibition or
genetic defects are associated with immune deﬁciency and increased risk of infection, in particular in DM [13]. In
addition, NOX2 has been suggested to be involved in an excessive and unlikely number of disease models [5], which
indicates a possible positive publication bias, as shown by a meta-analysis of NOX2 studies in stroke [88], or an
epiphenomena without therapeutic relevance.
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Glossary
Atherosclerosis: the narrowing of
arteries due to plaque build-up on
the arterial wall, a chronic
inﬂammatory condition of large- to
medium-sized arteries and major
cause of cardiovascular disease.
Glomerular hyperﬁltration: a
condition of abnormally high
glomerular ﬁltration rate in the kidney,
which occurs as early manifestation
of diabetic nephropathy.
Insulin resistance: a state whenIn addition to preventing ROS synthesis and metabolism, ROS-induced damage can also be
repaired at both the molecular and functional level. This is exempliﬁed by recoupling of
uncoupled NOS, allosteric sensitization of the nitric oxide (NO) receptor, sGC, for lowered
NO levels, and the activation of oxidatively damaged, heme-free apo-sGC by heme-mimetics,
respectively [3,5]. Collectively, these discoveries have revolutionized the ﬁeld of ROS in general
and, as indicated by one of ﬁrst clinical applications, DM.
We here review, ﬁrst, the physiological roles of ROS (e.g., NO, H2O2, superoxide, and
peroxynitrite) in insulin secretion and signaling (Box 2), as well as in physiology and patho-
physiology of organs affected by functional and structural damage due to type 2 DM (T2DM).
Importantly, the sources and mechanisms of ROS differ in health, early and late stages ofbody cells do not respond sufﬁciently
to insulin and a driving factor leading
to T2DM.
NADPH oxidase: a membrane-
bound enzyme family which consists
of seven members, NOX1–5 and two
dual oxidases (DUOX1 and 2). They
are the only known dedicated source
of ROS and have no other function.
Nitric oxide synthase (NOS): a
family of enzymes that consists of
three isoforms; NOS1–3, catalyzing
the formation of NO, an important
cellular signaling molecule, from L-
arginine.
Nuclear factor (erythroid-derived
2)-like 2 (NRF2): a transcription
factor that regulates the expression
of cytoprotective and antioxidant
proteins.
Oxidative stress: an outdated view
of ROS as primarily toxic metabolic
waste products that need to be
controlled by antioxidant enzymes or
antioxidant drugs.
Reactive oxygen species (ROS): a
collective term for compounds such
as superoxide, hydrogen peroxide,
hydroxyl radical, peroxynitrite, and
nitric oxide, although reactivity varies
greatly between individual members.
Redox balance hypothesis: an
outdated hypothesis that was
frequently used to describe a
supposedly neutral steady-state level
of ROS (i.e., balance between ROS
formation and cellular antioxidant
defense).
Renin-angiotensin system (RAS):
a hormone system which controls
blood pressure and sodium
homeostasis. Its effects are
coordinated through integrated
actions in the kidney, cardiovascular
system, and the central nervous
system.
Soluble guanylate cyclase (sGC):
a heme-containing enzyme that acts
as a receptor for NO to produce the
Box 2. Insulin and ROS
Pancreatic b Cells
The secretion of insulin from pancreatic b cells is mainly regulated by plasma glucose levels. Glucose is taken up via the
glucose transporter 2 (GLUT2) and thereafter oxidized to produce ATP. This leads to the closure of KATP channels,
depolarization of the plasma membrane, opening of voltage-dependent Ca2+ channels, and a subsequent increase in
intracellular Ca2+, which enables exocytotic insulin release [89]. Two ROS species, NO and H2O2, increase intracellular
Ca2+ and thereby facilitate insulin release. Low levels of NO from NOS1 do so by stimulating cGMP formation through
sGC, and cGMP in turn activates cGMP-dependent protein kinase (PKG), which inhibits KATP channels [90]; mitochon-
drial glucose metabolism leaks small amounts of superoxide, which, upon dismutation to H2O2, stimulates ryanodine
receptors to also increase intracellular Ca2+ [7,89]. Importantly, the use of ROS by pancreatic b cells comes at a risk.
Compared with most other cells, pancreatic b cells have some of the lowest expression and activity levels of ROS-
metabolizing (antioxidant) enzymes [7], making them more vulnerable than other cells to the potential cytotoxic effects of
ROS, such as DNA and protein damage.
In early stages of T2DM, production of NO and ROS begins to exceed the antioxidant resistance of pancreatic b cells.
Peripheral insulin resistance (see below) and high glucose and fatty acid levels trigger pancreatic b cells to
compensate by releasing more and more insulin in a mitochondrial ROS-dependent manner [91]. In later stages, this
mechanism is exhausted as superoxide anion induces a leak of protons across the mitochondrial inner membrane,
decreases the mitochondrial membrane potential and ATP production, and eventually leads to a lower insulin secretion
[92]. Moreover, upregulation of the renin-angiotensin system (RAS) and inﬂammatory cytokines further increase
superoxide overproduction from additional sources (Figure 1) (i.e., NOX1 and NOX2) [87]. The additional induction
of NOS2, which produces NO, toxiﬁes superoxide to yield peroxynitrite which not only further reduces insulin secretion
but also induces pancreatic b cell death [93].
Insulin-Sensitive Tissues
In peripheral insulin-sensitive tissues such as skeletal muscle, fat cells, and liver, insulin controls the switch from lipolysis/
fatty oxidation during fasting to lipid storage/glucose oxidation following feeding [94]. Binding of insulin to the insulin
receptor (IR) phosphorylates substrate proteins, IRS1 and IRS2, activating phosphatidylinositol 3-kinase (PI3K)-Akt
(protein kinase B) signaling, which leads to the translocation and activation of glucose transporters (mainly GLUT4 in
muscles and fat cells) and subsequent glucose uptake [94,95].
ROS come into play in insulin signaling through activation of PI3K and alternative protein kinase C (PKC) activation to
increase NOX4 activity, forming H2O2 [95]. H2O2 augments insulin-IR-PI3K signaling twofold, by inhibiting protein
tyrosine phosphatase 1B (PTP1B) and the phosphatase and tensin homologue, PTEN, which dephosphorylates IR and
downregulates PI3K signaling [94,95], and by activating MAP kinase phosphatase-1, which dephosphorylates IRS1
[96].
Further increased ROS production is associated with peripheral insulin resistance, a main feature of T2DM [97]. In early
stages of T2DM, NOX4 causes fat and liver cell apoptosis, ﬁbrosis, and inﬂammation [97,98]; NOX2 decreases skeletal
muscle insulin-induced Akt phosphorylation, GLUT4 expression and translocation, and thereby glucose uptake [99]. In
later stages, mitochondrial ROS formation is induced in skeletal muscles, fat cells, and liver, activating serine kinases
and further impeding insulin signaling [97,98]. In skeletal muscles, upregulation of the RAS system further activates
NOX2 to aggravate insulin resistance [99].
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second messenger cGMP, which
activates protein kinases and causes
vasodilation or regulates
phosphodiesterases.
Tubuloglomerular feedback: an
adaptive mechanism that links the
rate of glomerular ﬁltration to the
concentration of salt in the distal
tubules.
Uncoupled NOS: when NOS
enzymatic activity is uncoupled to
produce superoxide instead of NO.
This state usually occurs under
pathological conditions induced by
ROS.disease, and with respect to different cells and organs (Figure 1, Key Figure), sometimes even
qualitatively. These differences need to be carefully dissected and deﬁned for T2DM and its
characteristic complications as well as other conditions in order to allow future precision
antidiabetic interventions. With respect to ROS, the relevant therapeutic targets (see above)
form a causal signaling network and in T2DM will be best targeted by mechanism-based
network pharmacology, where multiple drugs are combined to synergistically correct a path-
ological into a near-physiological state [11]. These drugs include some new compound classes
that act directly on ROS sources and targets but also some registered drugs, which act, at least
in part, through indirectly modulating the ROS network. Finally, mechanism-based diagnostics
may enrich these new therapeutic approaches with respect to ROS and DM in order to stratify
patients for personalized and precision therapy.
ROS in Diabetic End-Organ Damage/Injury
The most patient-relevant end-organ complications in DM include chronic kidney disease
(CKD) (27.8% of patients with DM), retinopathies (18.9%), heart attack (9.8%), and stroke
(6.6%) [12]. In all of these, ROS have been suggested to play a causal role [13–15]. Collectively,
these represent major causes of disability and death in diabetics and are only moderately
prevented by most glucose-lowering antidiabetic drugs, in particular diabetic kidney disease
[16]. Although ROS play detrimental roles in these complications, certain ROS forms fulﬁl
important physiological functions in several organs, for example, NO, which is produced by
constitutive NOS enzymes (i.e., NOS1 and NOS3) and H2O2, which is produced by NOX4.
Some examples of these are discussed in the following sections.
Indeed, in T2DM, several events such as hyperglycemia, dyslipidemia, advanced glycation end-
products (AGEs), and upregulation of the renin-angiotensin system (RAS) contribute to detri-
mental ROS production. Despite the fact that many enzymes are, in principle, capable of forming
ROS, NOXs appear to often be the primary source and disease trigger [14]. Importantly, they
represent the only enzyme family with no other known function than to produce ROS [5]. All other
ROS sources have other primary functions and ROS production is a biochemical ‘accident’ often
requiring a prior (often ROS-induced) damage or uncoupling before ROS formation is initiated.
Therefore,wewill focus here on the role ofmain NOXisoforms (Box 1) indiabeticend-organ damage.
The roles played by other ROS sources, such as mitochondria and xanthine oxidase (XO), and the
ROS-toxifying enzyme, myeloperoxidase (MPO) as well as NRF2 are brieﬂy discussed in Box 3.
ROS in Blood Vessels
In a normal blood vessel wall, NO produced by NOS3 activates sGC, resulting in cGMP-
dependent inhibition of smooth muscle contraction. In human vascular cells, NO shows
atheroprotection by inhibiting leukocyte adhesion in endothelial cells and proliferation of
smooth muscle cells [17,18]. NO also displays antithrombotic properties in human endothelial
cells by inhibiting platelet adhesion and aggregation [18]. H2O2 produced by endothelial NOX4
enhances vasodilation in mice [8], both in a cGMP-dependent manner, by increasing the
expression and activity of NOS3 [19,20], and in a cGMP-independent manner, by oxidative
activation of protein kinase G I (PKGIa) [21]. Moreover, H2O2 is a key signal in angiogenesis in
both human and animal vascular cells [22,23].
Vascular Disease/Atherosclerosis
In blood vessels, ROS have been suggested to cause hypertension, atherosclerosis, and a
prothrombotic stage, either directly or by interfering with protective NO [13,24]. In large- and
medium-sized arteries, ROS-induced atherosclerosis is thought to be further accelerated by
DM [13]. Surprisingly, however, this does not account for all ROS; NOX4-derived H2O2 isTrends in Endocrinology & Metabolism, May 2019, Vol. 30, No. 5 315
Key Figure
Differential Roles of ROS in Physiology and DM
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Box 3. ROS Sources and Metabolism
Mitochondria, XO, and MPO
In addition to NOXs and uncoupled NOS, mitochondria and XO as alternative ROS sources, and MPO as an important
ROS-toxifying enzyme may also contribute to the pathogenesis of diabetic end-organ damage. XO produces ROS such
as superoxide and H2O2 during oxidative conversion of xanthine to uric acid [5]. Mitochondria produce superoxide, by
one electron reduction of O2, which is then dismutated to H2O2 by SOD [100]. MPO is a heme peroxidase expressed in
neutrophils and monocytes and is important for innate immune system. MPO converts NOX- or XO-derived H2O2 in
conjunction with halides and nitrite to more reactive species such as hypochlorous acid [5] and, in conjunction with
nitrite, represents an alternative source for peroxynitrite, besides the canonical NO and superoxide interaction [101].
Importantly, elevated XO activity and MPO levels correlate with the development of T2DM and diabetic end-organ
damage [102,103] (e.g., in kidney ﬁbrosis and proteinuria [104], neuropathy [105], and atherosclerosis [103]). Mito-
chondrial ROS also have been suggested as causative factors of insulin resistance and implicated in initiation and
progression of diabetic complications [14]. Therefore, targeting mitochondria, XO, and MPO may be of additional beneﬁt
in DM and, indeed, mitochondrial-targeted antioxidants, XO, and MPO inhibitors are in clinical development (see below)
(Table 1).
NRF2
Besides ROS-forming and -metabolizing enzymes, there appears to also be a therapeutic option via endogenous ROS-
eliminating (antioxidant) enzymes, in particular those genetically regulated by the transcription factor NRF2. In vascu-
lature, NRF2 is stimulated in response to steady laminar shear stress and ROS to promote atheroprotection. Con-
versely, oscillatory shear stress and endothelial dysfunction are associated with decreased NRF2 activity and
atherogenesis [106]. In the diabetic milieu, NRF2 and its target genes increase in response to hyperglycemia and
high fat, suggesting adaptive activation against increased ROS [107]. However, chronic hyperglycemia and prolonged
ROS production inhibit NRF2 activation, which is associated with endothelial cell death and foam cell formation [108]. In
the diabetic kidney, high glucose and increased ROS production are accompanied by NRF2 upregulation, which initially
protects against injury via inhibition of TGF-b and accumulation of extracellular matrix [109]. Sustained hyperglycemia
and formation of AGEs, however, downregulate NRF2 and decrease its activity in the kidney, which is associated with
increased ﬁbrosis and renal dysfunction [110]. Moreover, in CKD patients, a decrease in the NRF2 signature of
peripheral blood mononuclear cells correlates with increased NF-kB related proinﬂammatory responses [111]. Retinal
NRF2 activation is increased in DM, which is thought to protect against ROS overproduction and inﬂammatory cytokines
as well as blood–retina barrier dysfunction, however, the DNA binding activity of NRF2 is decreased [112]. Similarly, in
diabetic nerves, acute and chronic hyperglycemia are associated with increased and decreased levels of NRF2,
respectively [113]. Thus, in addition to NOX, XO, MPO, NOS, and sGC, NRF2 also has to be considered for the
treatment or prevention of diabetic end-organ damage and all of these targets may form a causal inter-related signaling
network for mechanism-based network pharmacology (Figure 2).antiatherosclerotic by reducing ﬁbrosis and proliferation of smooth muscle cells [25]. Con-
versely, a different type and source of ROS (i.e., NOX1- [13] and possibly NOX5-derived [26]
superoxide), may be proatherosclerotic in DM. These examples show the complexity of ROS
pathobiology with different sources/types of ROS having qualitatively opposing effects, making
precise targeting of the most disease-relevant isoform pertinent for any chronic therapy in
T2DM. Nonspeciﬁc, chronic NOX inhibition may interfere with angiogenesis, collateral forma-
tion, capillarization, and may also be proatherosclerotic and immunocompromising.Figure 1. Panels in (A) depict physiologic effects of ROS; (B), pathological changes in early DM; (C), late-stage DM end-
organ damage. In each row, the black boxes on the left represent pancreatic b cells; red in the middle, renal cells; green
and blue on the right, endothelial and vascular smooth muscle cells, respectively. Black arrows and red blocks represent
stimulatory and inhibitory effects, respectively. ROS mediate both physiological and pathophysiological signaling.
Mechanisms can be enhanced (bold black text and arrows) or diminished (small/transparent text and arrows) leading
to pathological changes that are implicated in early and late stages of DM. Abbreviations: Ang II, angiotensin II; DM,
diabetes mellitus; FFA, free fatty acids; GLUT, glucose transporter; H2O2, hydrogen peroxide; IR, insulin receptor; NO,
nitric oxide; NOS, nitric oxide synthase; NOX, NADPH oxidase; O2, superoxide; PI3K, phosphatidylinositide 3-kinase;
PKC, protein kinase C; ROS, reactive oxygen species; sGC, soluble guanylate cyclase.
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Superoxide appears to be the most disease-relevant type of ROS. It can decrease NO
biophase levels by direct chemical scavenging, leading to intermediate peroxynitrite, protein
tyrosine nitration, reducing endothelial insulin receptor expression, and inhibiting phosphati-
dylinositol 3-kinase (PI3K)-Akt-NOS3 signaling in the endothelium [24,27] (Figure 1). In addition,
superoxide uncouples NOS3, which decreases NO production and simultaneously increases
superoxide production from uncoupled NOS3 [9] (i.e., an example of ROS-induced ROS). This
has also been coined as the ‘kindling-bonﬁre-radical’ hypothesis [28] (Figure 1), because the
total amounts of ROS formed from uncoupled NOS can eventually exceed those of the initial
trigger enzyme, NOX. Finally, superoxide and/or peroxynitrite can damage the NO receptor,
sGC [29,30], leading to a collectively threefold interruption of NO-cGMP signaling by:
(i) scavenging of NO, (ii) uncoupling NOS3, and (iii) damaging the NO receptor sGC.
ROS in the Kidney
In normal kidney, ROS regulate urine excretion and blood pressure, and H2O2 stimulates
prorenin-induced sodium reabsorption in mouse kidney [31] and vasodilates intrarenal arteries
from human and rat through indirect NO-dependent mechanisms [19,32]. NO promotes
natriuresis in animals by inhibiting tubular sodium reabsorption [33], promotes diuresis by
increasing both total and regional renal blood ﬂow through functional antagonism of the
vasoconstrictor tone induced by renal sympathetic neurons [33,34], and blunts the tubulo-
glomerular feedback response by afferent arteriolar dilatation [35].
Diabetic Kidney Disease
Besides ROS, multiple inﬂammatory, ﬁbrotic, and apoptotic signaling pathways are also
implicated in the different stages of diabetic kidney disease. ROS, however, appear to integrate
these and thereby play a crucial role in the initiation and progression of diabetic end-organ
damage and thus represent an ideal target [14]. For this, diabetic nephropathy represents the
clinically most advanced therapeutic approach (Table 1), where disease-relevant (not protec-
tive!) H2O2 is produced from NOX4, and superoxide, from NOX5. Despite being chemically
distinct, both ROS seem to trigger kidney ﬁbrosis, renal hypertrophy, and albuminuria [36,37].
H2O2 also increases the expression of vascular endothelial growth factor (VEGF) and proﬁbrotic
markers [36] and induces glomerular hyperﬁltration, possibly by increasing intrarenal NOS
expression [38]. While the disease progresses, several other renal mediators, such as angio-
tensin II, AGEs, transforming growth factor (TGF)-b, and protein kinase C (PKC), further
increase the activity of NOX enzymes, resulting in a further aggravated renal damage [14].
Impaired cGMP signaling by ROS uncoupling of NOS3 and oxidizing sGC (Figure 1) may further
aggravate tubulointerstitial damage and ﬁbrosis [39].
ROS in Other Organs
In the retina, NO is necessary for visual function by increasing retinal blood ﬂow, to maintain
adequate nourishment and meet the high metabolic demand of the retina. In animal retina, NO
modulates synaptic transmission from photoreceptors and activates sGC to produce cGMP,
which is a key intermediate in the visual transduction cascade (reviewed in [40]). H2O2 may also
act as an intracellular messenger in the human retina. Its physiological roles, however, are
unclear [41].
In the brain of animals, NO functions as a neurotransmitter and neuromodulator, regulating
synaptic plasticity, which is involved in cognitive functions such as memory formation and
mediates neurovascular coupling [42]. H2O2 contributes to neurogenesis and differentiation,
and neuronal plasticity [43]. In the peripheral nervous system of animals, NO also serves as a
neurotransmitter of so-called nonadrenergic-noncholinergic nerves, which induce smooth318 Trends in Endocrinology & Metabolism, May 2019, Vol. 30, No. 5
Table 1. Mechanism-Based Therapeutics and Their Clinical Status
Compound Mechanism of action Pathology Clinical status
GKT137831 NOX1, NOX4, NOX5 inhibitor
T2DM nephropathy Safe in Phase I clinical trial
Failed to reduce albuminuria in a short-term
Phase II trial (NCT02010242)
T1DM nephropathy Clinical trial ongoing (U1111-1187-2609)
Primary biliary cirrhosis Phase II clinical trial ongoing (NCT03226067)
Ronopterin (VAS203) NOS2 inhibitor
Traumatic brain injury Phase III clinical trial (NCT02794168)
Renal function in
healthy volunteers
Safe in Phase I clinical trial (NCT02992236)
Allopurinol XO inhibitor T1DM nephropathy Phase IV (NCT02829177)
AZD3241 MPO inhibitor Multiple system atrophy Phase II (NCT02388295)
AZD4831 MPO inhibitor Heart failure Phase II (NCT03756285)
MitoQ Mitochondrial-targeted antioxidant Chronic kidney disease Declared as dietary supplement without
indication or application in Phase IV
(NCT02364648)
SkQ1 Mitochondrial-targeted antioxidant Dry-eye syndrome Phase III (NCT03764735)
Folic acid NOS recoupling agent T2DM nephropathy Failed to improve renal endothelial function or
reduce albuminuria in a Phase III clinical trial
(NCT00136188)
L-citrulline NOS recoupling agent
Vascular dysfunction in T2DM Clinical trial ongoing (NCT03358264)
Peripheral artery disease Phase III clinical trial ongoing (NCT02521220)
Sickle cell disease Phase I trial ongoing (NCT02697240)
Riociguat sGC stimulator
Pulmonary hypertension In the clinic
Scleroderma Phase II trial ongoing (NCT02915835)
Sickle cell disease Phase II trial ongoing (NCT02633397)
Vericiguat sGC stimulator Heart failure Phase III clinical trial (NCT02861534)
Olinciguat (IW-1701) sGC stimulator
Type I or II achalasia Phase II clinical trial ongoing (NCT02931565)
Sickle cell disease Phase II clinical trial ongoing (NCT03285178)
Praliciguat (IW-1973) sGC stimulator
Heart failure with preserved
ejection fraction
Phase II trial ongoing (NCT03254485)
T2DM and hypertension Phase II trial completed (NCT03091920)
Nelociguat (BAY60-4552) sGC stimulator Chronic heart failure Phase I completed (NCT00565565)
Ataciguat sGC activator Aortic valve calciﬁcation Phase II clinical trial (NCT02481258)
Bardoxolone methyl NRF2 activator
T2DM and stage 4 CKD Increased estimated GFR, but did not improve
proteinuria and was associated with
cardiovascular toxicity in Phase III clinical trial
(NCT01351675).
T2DM and CKD Increased measured GFR with no heart failure
events due to ﬂuid retention in Phase II clinical
trial (NCT02316821)
CKD associated with T1DM Phase II clinical trial (NCT03366337)
CXA-10 NRF2 activator
Pulmonary arterial hypertension Phase II clinical trial ongoing (NCT03449524)
Primary focal segmental glomerulosclerosis Phase II clinical trial ongoing (NCT03422510)
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muscle relaxation [42]. H2O2 stimulates axon growth and nerve regeneration [43,44]. The
human cell culture data [17,18,23,32,41] as well as the results in animals described above, if
translatable to humans, would suggest that ROS contribute signiﬁcantly and in multiple
manners to human physiology.
Other End-Organ Complications
In diabetic retinopathy, H2O2 production is increased from an upregulated NOX4, resulting in
increased VEGF expression and blood–retina barrier damage [45]. Moreover, NOX1 is acti-
vated to produce superoxide, which promotes cell death [46]. In chronic diabetic neuropathy,
ROS from a yet undeﬁned isoform of NADPH oxidase are associated with neuronal apoptosis
[47]. In acute ischemic stroke [48], NOX4 is the main source of deleterious ROS and induces
blood–brain barrier (BBB) damage and neuronal cell death [15,49]. In the setting of DM,
additional isoforms (e.g., NOX1 and NOX5) may come into play.
Mechanism and Network-Based Redox Therapies
Considering the failure of classic antioxidants in clinical trials focusing on diabetic complications
[50,51], new therapeutic approaches (i.e., mechanism-based redox therapies) are now state-
of-the-art for future trials. These approaches include targeting speciﬁc ROS sources using
pharmacological inhibitors, repairing ROS-induced damage, or upregulating endogenous
antioxidant enzymes (Figure 2). The clinical status of these therapies is listed in Table 1.
Importantly, targeting the ROS signaling network at multiple sites in a synergistic combinatorial
manner enables a shift from single target approaches to network pharmacology, facilitating
lower therapeutic doses with fewer side effects.
Drugs Targeting ROS Sources
NOX Inhibitors
Several NOX inhibitors exist [3]. However, none of them are isoform speciﬁc. The NOX1/4
inhibitors, GKT137831 and GKT136901, have shown beneﬁcial effects in several preclinical
studies addressing diabetic complications [13,36]. GKT137831 is currently the only NOX
inhibitor in clinical trials focusing on diabetic nephropathy. It was safe in a Phase I trial, however
failed to reduce albuminuria in a short-term Phase II trial in patients with T2DM and advanced
nephropathy on maximal RAS blockade. Yet, there were positive signals on reduction of
systemic inﬂammatory markers. Another trial is currently investigating the antialbuminuric effect
of GKT137831 in type 1 diabetic nephropathy. This compound is also being tested in a clinical
trial for primary biliary cirrhosis (Table 1).
In addition to GKT137831, other NOX inhibitors showed promising results in preclinical studies
well, the pan-NOX inhibitor, APX-115, protects against nephropathy in a mouse T2DM model
and was superior to GKT137831 in preserving renal function [52]. VAS2870, another pan-NOX
inhibitor, reduces aortic contractility in diabetic rats by improving endothelial function [53] and,
in stroke, stabilized the BBB, provided neuroprotection, improved neurological scores in mice
[15], and inhibited reperfusion-induced hemorrhagic transformation in hyperglycemic rats [54].
Clearly, isoform-speciﬁc NOX inhibitors together with further testing in clinical trials focusing on
diabetic complications are needed.
NOS Inhibitors
Despite its many beneﬁcial actions, NO may also have detrimental effects when overproduced.
After ischemic stroke, for example, overproduction of NO by NOS1 induces cell death and BBB
hyperpermeability and in preclinical studies both nonselective NOS inhibitors or selective
NOS1/2 inhibitors improved post-stroke outcome [55]. Thus far, however, no clinical trial320 Trends in Endocrinology & Metabolism, May 2019, Vol. 30, No. 5
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Figure 2. Network Pharmacology for ROS-Mediated Disease States. In DM, high glucose and activated renin-angiotensin system (ACE/Ang II/AT1R) lead to
the production of superoxide from NOXs and XO, and H2O2 from NOX4. Superoxide interferes with NO/cGMP/PKG signaling by: (i) scavenging NO to form highly
reactive ONOO, (ii) uncoupling of NOS, and (iii) oxidation of sGC to form heme-free and NO-unresponsive apo-sGC. Proteins can be nitrated by ONOO or MPO/
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proteins (in blue) indicate targets and biomarkers of ROS and cGMP signaling potentially suitable for diagnosing ROS-related disease states and patient stratiﬁcation.
Abbreviations: ACE, angiotensin converting enzyme; Ang II, angiotensin II, ARB, angiotensin receptor blockers; ARE, antioxidant responsive element; AT1R,
angiotensin II receptor type 1; DM, diabetes mellitus; H2O2, hydrogen peroxide; MPO, myeloperoxidase; MPOi, MPO inhibitors; NO, nitric oxide; NOS, nitric oxide
synthase; NOSi, NOS inhibitors; NOSr, NOS recoupling agents; NOX, NADPH oxidase, NOXi, NOX inhibitors; NRF2, nuclear factor (erythroid-derived 2)-like 2; NRF2a,
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has tested NOS inhibitors in a stroke setting. VAS203, a pan-NOS inhibitor, is currently in a
Phase III clinical trial (NOSTRA-III) in a related, yet not diabetic indication (i.e., patients with
traumatic brain injury).
Drugs Targeting Other ROS Sources
Selective inhibitors of XO and MPO and mitochondrial-targeted antioxidants represent prom-
ising drugs for treatment of DM-related organ injury. XO inhibitors such as allopurinol and
febuxostat, which are used because of their uric acid-lowering effects for treatment of gout
patients, are now also tested in clinical trials because of their ROS-lowering effects and are
focused on DM [e.g., in diabetic nephropathy and diabetic coronary artery disease (ALLIENCE
trial)]. In addition, MPO inhibitors, verdiperstat (AZD3241) and AZD4831, and mitochondrial-
targeted antioxidants MitoQ and SkQ1 are being tested clinically, albeit in nondiabetic con-
ditions (Table 1).
Drugs Targeting ROS Targets
NOS Recoupling
Uncoupling of homodimeric NOS enzymes occurs by multiple mechanisms, i.e., competition of
the substrate arginine with asymmetric dimethyl-L-arginine (ADMA), reduced availability of the
cofactor BH4, or oxidative damage and monomerization [56]. All of these mechanisms can be
triggered by ROS. Moreover, uncoupled NOS will produce superoxide instead of NO, leading to
further ROS accumulation and cellular dysfunction and damage. Several NOS recoupling
strategies reduce diabetic complications by improving endothelial dysfunction in humans
and animals (reviewed in [56]). Recently however, high-dose folic acid, which increases
BH4 content, failed in a Phase III clinical trial to improve renal endothelial function or to reduce
albuminuria in patients with DM (NCT00136188). Studies on L-arginine supplementation gave
conﬂicting results, probably due to its low oral bioavailability (reviewed in [57]). L-citrulline
supplementation could be a better alternative due to its ideal pharmacokinetics and is currently
in a Phase II clinical trial (CIPER) for treatment of peripheral artery disease. Preclinically, 3 weeks
of L-citrulline treatment protected from glomerular hyperﬁltration and proteinuria in streptozo-
tocin (STZ)-diabetic rats, whereas arginine did not [58].
sGC Stimulators and Activators
ROS can also damage the NO receptor, sGC [30], resulting in impaired responsiveness to NO in
DM-associated organ injury [59]. This can be functionally repaired by two different classes of
drugs, sGC stimulators and activators. The former can synergize with low levels of endogenous
NO by allosterically binding to sGC, while the latter bind to oxidatively damaged, heme-free
apo-sGC, which can no longer sense NO. sGC activators fully recover cGMP formation from
apo-sGC and prevent its degradation [59,60]. Preclinical studies of diabetic complications
using sGC stimulators and activators, respectively, show promising results. In diabetic NOS3-
deﬁcient mice (a model of late-stage diabetic nephropathy) the sGC stimulator, riociguat,
combined with an angiotensin receptor blocker (ARB) signiﬁcantly reduced albuminuria when
compared with treatment with ARB alone [61]. The sGC activators, Bl703704 and cinaciguat,
showed beneﬁcial outcomes on renal function and improved renal structure in diabetics,
respectively [39,59]. HMR1766 (ataciguat), another sGC activator, improved NO/cGMP sig-
naling and attenuated platelet activation in diabetic rats [62]. In addition, in a stroke model,
treatment with the sGC activator, BAY 60-2770, decreased mortality, increased cerebral blood
ﬂow, decreased infarct size, attenuated BBB damage and protected from neuronal apoptosis
[63]. Recently, riociguat has been approved for treatment of pulmonary hypertension and
together with other sGC stimulators and activators is being tested in clinical trials, albeit so far
only in nondiabetic disease conditions (Table 1).322 Trends in Endocrinology & Metabolism, May 2019, Vol. 30, No. 5
Clinician’s Corner
Apart from lifestyle changes, none of
the current antidiabetic therapies are
curative as they do not target a disease
mechanism, but rather focus on nor-
malizing surrogate parameters or risk
factors such as blood glucose or
hypertension.
One proposed causal disease mecha-
nism involves reactive oxygen species
(ROS), but exogenous antioxidants
have failed in clinical outcome trials
possibly due to the fact that ROS also
have physiological functions.
New approaches, now in clinical devel-
opment, include the activation of
endogenous antioxidant responses,
inhibition of disease-relevant enzy-
matic sources of ROS, or the (func-
tional) repair of damage induced by
ROS. This includes NRF2 activators,
NADPH oxidase (NOX) inhibitors, and
soluble guanyl ate cyclase (sGC) stim-
ulators and activators, respectively.
Moreover, targeting the ROS signaling
network with several drugs at different
sites concurrently (network pharma-
cology) may enable usage of lower
doses of each drug and possible fewer
adverse side effects.
Ideally, new mechanism-based bio-
markers will stratify patients that suffer
from a dysfunction of ROS signaling to
enable precision medicine.NRF2 Activators
Induction of endogenous ROS metabolizing/eliminating enzymes by activating NRF2 boosts
the endogenous control of physiological ROS signaling. Hence, NRF2 activation may be a
promising approach to treat ROS-associated diseases, despite the failure of systemically
applied antioxidants, which by deﬁnition interfere with any ROS, physiological or pathophysi-
ological, leading to neutral or even detrimental outcomes. In a Chinese cohort of T2DM
patients, the AA allele of the rs6721961 polymorphism in the NRF2 gene is associated with
lower total antioxidative capacity and pancreatic b cell function and increased risk of newly
diagnosed T2DM [64]. Therefore, mild systemic activation of NRF2 may elicit protective
effects against hyperglycemia and related end-organ damage. Several NRF2 activators,
including sulforaphane and different synthetic triterpenoids, have promising effects in pre-
clinical models of diabetic complications (reviewed in [4,65]). For instance, in ApoE-deﬁcient
mice rendered diabetic by STZ injections, a low dose of the potent triterpenoid, dh404,
protected against atherosclerosis and improved both renal function and structure. The study
also demonstrated target engagement of dh404 on NRF2 activation by reduced ROS and
attenuated proinﬂammatory and proﬁbrotic markers [66]. Another triterpenoid, RTA-405,
improved renal function, serum glucose, and triglyceride levels in STZ-induced diabetic rats
when compared with untreated diabetic rats [67]. Both dh404 and RTA-405 do not show
adverse effects on kidney or liver in obese rats with T1DM [67]. The most developed
triterpenoid for clinical use in DM is bardoxolone methyl. In a Phase II clinical trial (BEAM),
bardoxolone methyl increased the estimated glomerular ﬁltration rate (GFR) in patients with
DM and moderate to severe CKD and this effect persisted for the whole treatment period of
52 weeks [68]. In a Phase III trial (BEACON), bardoxolone methyl increased estimated GFR in
patients with T2DM and stage 4 CKD [69]. The trial was terminated prematurely after
preliminary analyses showed that patients randomized to bardoxolone methyl experienced
signiﬁcantly higher rates of heart failure events in the ﬁrst 4 weeks of the trial. Elevated brain
natriuretic peptide and a history of congestive heart failure were identiﬁed as risk factors that
led to ﬂuid overload events in post-hoc analyses and have been used to mitigate risk in further
clinical trials with bardoxolone methyl. The cardiovascular adverse effects of bardoxolone
methyl may be associated with modulation of the endothelin pathway, leading to sodium and
volume retention and to blood pressure elevation in this subset of at-risk individuals [70]. In
fact, in the Phase 2 TSUBAKI trial assessing bardoxolone methyl in Japanese patients with
stage 3 and 4 CKD associated with T2DM, no ﬂuid retention-related adverse events were
observed, indicating that the risk-mitigation criteria could be applied to future studies as well
[71]. A new Phase 3 trial (AYAME) is being conducted in Japan to assess the efﬁcacy of
multiple doses of RTA 402, using time-to-onset of a 30% decrease in estimated GFR from
baseline or end-stage renal disease.
Indirect ROS Modulation
The current standard treatment for DM and its complications involves normalizing glucose,
blood pressure, and dyslipidemia. These interventions delay microvascular complications and
are used for chronic treatment of the macrovascular complications of DM. Some of these
treatment principles possess redox components, which may contribute to their beneﬁcial
effects on diabetic complications.
RAS
Drugs that block the RAS, such as angiotensin-converting enzyme inhibitors and ARB, are
currently used to delay the progression of diabetic nephropathy. These drugs inhibit ROS
production in different DM-associated conditions by indirectly lowering NOX expression and/
or activity [48,72]. RAS blockers also improve endothelial dysfunction and repair the damageTrends in Endocrinology & Metabolism, May 2019, Vol. 30, No. 5 323
Outstanding Questions
Will network pharmacology of speciﬁc
ROS sources and targets in different
stages of diabetes improve patient-rel-
evant outcomes?
Are there additional sources and tar-
gets of ROS in diabetes for mecha-
nism-based therapy?
Is there clinical synergy between direct
and indirect modulators of ROS in
diabetes?
Will most of the current glucose-low-
ering, symptomatic but not mecha-
nism-based antidiabetics become
obsolete in the not too far future?
Would effective lifestyle management
programs of diabetes make pharma-
cotherapy obsolete in 90% of all dia-
betes patients? Is pharmacotherapy
effective and safe in patients who do
not succeed in lifestyle changes?
How can mechanism-based diagnos-
tics help to stratify diabetes patients for
early diagnosis, prevention, and cura-
tive therapy?induced by ROS in DM via recoupling of NOS [72,73]. In addition, ARB increase the
endogenous antioxidant, superoxide dismutase (SOD), via inhibition of NOX and activation
of NRF2 in kidneys of diabetic mice [74].
Statins
Statins as cholesterol-lowering and anti-inﬂammatory [75] drugs are frequently used as part of
DM care to lower the risk of cardiovascular complications [76]. With respect to ROS, statins
inhibit the activation of RAC1, which is required for the activation of NOX, and in DM improve
endothelial dysfunction by also inducing recoupling of NOS3 [76,77].
Glucose-Lowering Drugs
Antihyperglycemic medications are commonly used to normalize glucose levels and include
biguanides (metformin), glitazones, dipeptidyl peptidase-4 (DDP-4) inhibitors, and glucagon-
like peptide-1 (GLP-1) agonists. With respect to ROS, NOX inhibition, NOS recoupling, and
activation of endogenous antioxidant enzymes are all suggested mechanisms of action of these
drugs [78–81]. Metformin is the ﬁrst-line therapy for T2DM patients and is being tested in
several clinical trials (more than 2000 on https://www.clinicaltrials.org) in diabetic and nondia-
betic conditions, including cancer. Metformin indirectly inhibits NOX via activation of AMP-
activated protein kinase (AMPK) and recouples NOS via upregulation of GTP cyclohydrolase 1
and thus BH4 levels [82]. Metformin also activates the endogenous NRF2 antioxidant pathway
via activation of AMPK [81]. Sodium-glucose cotransporter-2 (SGLT2) inhibitors, including
empagliﬂozin, dapagliﬂozin, canagliﬂozin, and ipragliﬂozin, have been recently approved as
antihyperglycemic therapies. These drugs possess several favorable effects in T2DM patients,
such as improved insulin sensitivity, weight loss, uric acid lowering, and blood pressure
reduction and show potentially direct cardiovascular and kidney beneﬁts [83]. In addition to
their glycosuric and natriuretic effects, several mechanisms have been suggested to explain
these beneﬁts, such as indirect inhibition of ROS production by NOX, recoupling of NOS, and
activation of cGMP signaling [84–86].
Concluding Remarks and Future Perspectives
Theoretical and experimental evidence suggests a fundamentally new approach towards
the contribution of ROS to T2DM and its pharmacological targeting. Instead of viewing
ROS primarily as a metabolic by-product or waste, they are in fact essential signaling
molecules with physiological and, upon dysregulation, also pathological roles. This dual
quality of ROS depends on: (i) the type of ROS, (ii) the ROS sources, (iii) the ROS targets,
and (iv) different functional consequences over time. Importantly, given the failure of classic
antioxidant regimes in clinical trials, the ﬁeld of ROS needs to evolve towards mechanism-
based, precision medicine. Given the apparent safety of NOX inhibitors, the high efﬁcacy of
NRF2 activators in Phase III clinical trials, and the recent discovery of sGC stimulators and
activators, clinical approaches of these targets in DM are ongoing or foreseeable in the very
near future. These may also include their combination in a mechanism-based network
pharmacology approach. Moreover, a better understanding of the causative mechanisms
related to ROS formation in the development and progression of DM and its complications
will allow identiﬁcation of susceptible patients and more precise prevention and treatment
(see Clinician’s Corner). Indeed, development of mechanism-based diagnostics will allow
early disease detection before the development of complications. Existing ROS biomark-
ers need to be validated in larger sample sizes and compared with current clinical
diagnostic tools to establish them clinically (see Outstanding Questions). In any case,
lifestyle changes need to be the primary intervention; pharmacotherapy only the ultima
ratio.324 Trends in Endocrinology & Metabolism, May 2019, Vol. 30, No. 5
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